logo
  • Home
  • Mechanism of Action
  • Efficacy Profile
    • Efficacy Profile
    • Efficacy F-VASI
    • Efficacy T-VASI
    • Ruxolitinib Cream Case Reports
  • Safety Profile
  • Dosing
  • Setting Expectations
  • Download
  • Patient Support

Setting Expectations

headerImg
headerImg

The following checklist may help with setting patient expectations.

Repigmentation takes time.'
Time to repigmentation varies depending on body location, and from patient to patient.'
Twice daily application to the affected areas.2
After successful re-pigmentation discuss maintenance strategies with patients.

Repigmentation Develops Best in the Hair-bearing Regions.

REPIGMENT FAST

Areas with a higher density of hair follicles respond more rapidly to treatment.

face
Face
Arms
Arms
Legs
Legs
Torso
Torso

REPIGMENT SLOWLY

Areas with lower density respond more slowly.

hands
M Back of hands & fingers
Feet
Feet & toes

MAY NOT REPIGMENT

Areas where hair follicles are absent or in low density.

Palms
Palms
Soles
Soles

Repigmentation May Occur in One of Multiple Patterns, Including:

Perifollicular

The most common pattern is the perifollicular pattern, which appears as small, round, repigmented areas around the hair follicles.

Perifollicular

Marginal

The marginal pattern appears as a repigmented rim at the lesion borders.

Marginal

Combined
Involves multiple patterns, such as marginal and perifollicular.

References:
  1. 3.Lumirix® Prescribing Information for Hong Kong.
  2. 8. Birlea SA, Goldstein NB, Norris DA. Repigmentation through melanocyte regeneration in vitiligo. Dermatologic clinics. 2017 Apr 1;35(2):205-18.
  3. 10. Rosmarin D, Sebastian M, Amster M, et al. Facial and total vitiligo area scoring index response shift during 104 weeks of Ruxolitinib cream treatment for vitiligo: results from the open-label arm of the TRuE-V long-term extension phase 3 study. Presented at the American Academy of Dermatology Annual Meeting; March 17–21, 2023; New Orleans, LA.
  4. 12. Harris JE, Papp K, Forman SB, et al. Relapse and maintenance of clinical response in the randomized withdrawal arm of the TRuE-V long-term extension phase 3 study of ruxolitinib cream in vitiligo. Presented at the American Academy of Dermatology Annual Meeting; March 17–21, 2023; New Orleans, LA.
  5. 13. Yang K, Xiong X, Pallavi G, Ling Y, Ding F, Duan W, Sun W, Ding G, Gong Q, Zhu W, Lu Y. The early repigmentation pattern of vitiligo is related to the source of melanocytes and by the choice of therapy: a retrospective cohort study. International Journal of Dermatology. 2018 Mar;57(3):324-31.

Get in Touch With Us.

At Rxilient, we believe in empowering patients and healthcare providers with the tools and information needed to achieve the best outcomes. Explore our collection of downloadable guides, tips, and educational materials to stay informed and confident throughout your treatment.

Leave your contact details and we will get in touch with you as soon as we can.

TERMS of use Privacy policy
footerLogo

Rxilient Medical (Hong Kong) Limited Unit 2106, 21st Floor, Island Place Tower, No. 510 King’s Road, North Point, Hong Kong Tel: +852 2369 3889

For healthcare professionals practising in Hong Kong only. LUM/HKG/DOC-101/ 2025/rev.01

Scan to download Lumirix® Prescribing Information

QRCode

Copyrights © 2025 All Rights Reserved

icon

Are you a healthcare professional from Hong Kong?

icon

This site is intended for healthcare professionals practising in Hong Kong only.

icon

Access Restricted

This site is intended for healthcare professionals practising in Hong Kong only.

You do not have permission to access this content.

Access denied. Please contact the site administrator for assistance.